Molecular pathology of the basement membrane zone in heritable blistering diseases:: The paradigm of epidermolysis bullosa

Matrix Biology

Volumn 57-58, Issue , 2017, Pages 76-85

  Uitto, Jouni ^a   Has, Cristina ^b   Vahidnezhad, Hassan ^a,c   Youssefian, Leila ^a   Bruckner Tuderman, Leena ^b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b UNIVERSITY OF FREIBURG   (Germany)

^c PASTEUR INSTITUTE OF IRAN   (Iran)

Author keywords

Cutaneous basement membrane zone; Epidermolysis bullosa; Heritable blistering diseases; Type VII collagen

Indexed keywords

ALPHA3 INTEGRIN; ALPHA6BETA4 INTEGRIN; BULLOUS PEMPHIGOID ANTIGEN 1; COLLAGEN TYPE 4; COLLAGEN TYPE 7; CYTOKERATIN 14; CYTOKERATIN 5; DESMOPLAKIN; KALININ; LAMININ 10; PLAKOGLOBIN; PLECTIN; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; VERY LATE ACTIVATION ANTIGEN 3; VON WILLEBRAND FACTOR; COL7A1 PROTEIN, HUMAN; SCLEROPROTEIN;

ALLELE; BASEMENT MEMBRANE; BLISTER; CELL THERAPY; DISEASE CLASSIFICATION; DISEASE COURSE; EPIDERMIS; EPIDERMOLYSIS BULLOSA; HEMIDESMOSOME; HUMAN; INTERMEDIATE FILAMENT; INTRACELLULAR TRANSPORT; KERATINOCYTE; LAMINA DENSA; LAMINA LUCIDA; MISSENSE MUTATION; MOLECULAR PATHOLOGY; NONHUMAN; PAPILLARY DERMIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN STRUCTURE; REVIEW; SKIN CARCINOMA; CHEMISTRY; CLASSIFICATION; GENE EXPRESSION; GENETIC HETEROGENEITY; GENETICS; GENOTYPE; METABOLISM; MUTATION; PATHOLOGY; PREIMPLANTATION GENETIC DIAGNOSIS; PRENATAL DIAGNOSIS; SEVERITY OF ILLNESS INDEX; SKIN;

BASEMENT MEMBRANE; COLLAGEN TYPE VII; EPIDERMOLYSIS BULLOSA; EXTRACELLULAR MATRIX PROTEINS; GENE EXPRESSION; GENETIC HETEROGENEITY; GENOTYPE; HUMANS; MUTATION; PHENOTYPE; PREIMPLANTATION DIAGNOSIS; PRENATAL DIAGNOSIS; SEVERITY OF ILLNESS INDEX; SKIN;

EID: 84994113132     PISSN: 0945053X     EISSN: 15691802     Source Type: Journal    
DOI: 10.1016/j.matbio.2016.07.009     Document Type: Review

References (62)

1. [1] Fine, J.D., Bruckner-Tuderman, L., Eady, R.A., Bauer, E.A., Bauer, J.W., Has, C., Heagerty, A., Hintner, H., Hovnanian, A., Jonkman, M.F., Leigh, I., Marinkovich, M.P., Martinez, A.E., McGrath, J.A., Mellerio, J.E., Moss, C., Murrell, D.F., Shimizu, H., Uitto, J., Woodley, D., Zambruno, G., Inherited epidermolysis bullosa: updated recommendations on diagnosis and classification. J. Am. Acad. Dermatol. 70 (2014), 1103–1126.
2. [2] Bruckner-Tuderman, L., Has, C., Disorders of the cutaneous basement membrane zone—the paradigm of epidermolysis bullosa. Matrix Biol. 33 (2014), 29–34.
3. [3] Uitto, J., Vahidnezhad, H., Youssefian, L., Genotypic heterogeneity and the mode of inheritance in epidermolysis bullosa. JAMA Dermatol. 152 (2016), 517–520.
4. [4] Pfendner, E.G., Sadowski, S.G., Uitto, J., Epidermolysis bullosa simplex: recurrent and de novo mutations in the KRT5 and KRT14 genes, phenotype/genotype correlations, and implications for genetic counseling and prenatal diagnosis. J. Invest. Dermatol. 125 (2005), 239–243.
5. [5] Varki, R., Sadowski, S., Pfendner, E., Uitto, J., Epidermolysis bullosa. I. Molecular genetics of the junctional and hemidesmosomal variants. J. Med. Genet. 43 (2006), 641–652.
6. [6] Heinonen, S., Männikkö, M., Klement, J.F., Whitaker-Menezes, D., Murphy, G.F., Uitto, J., Targeted inactivation of the type VII collagen gene (Col7a1) in mice results in severe blistering phenotype: a model for recessive dystrophic epidermolysis bullosa. J. Cell Sci. 112 (1999), 3641–3648.
7. [7] Jobard, F., Bouadjar, B., Caux, F., Hadj-Rabia, S., Has, C., Matsuda, F., Weissenbach, J., Lathrop, M., Prud'homme, J.F., Fischer, J., Identification of mutations in a new gene encoding a FERM family protein with a pleckstrin homology domain in Kindler syndrome. Hum. Mol. Genet. 12 (2003), 925–935.
8. [8] Siegel, D.H., Ashton, G.H., Penagos, H.G., Lee, J.V., Feiler, H.S., Wilhelmsen, K.C., South, A.P., Smith, F.J., Prescott, A.R., Wessagowit, V., Oyama, N., Akiyama, M., Al Aboud, D., Al Aboud, K., Al Githami, A., Al Hawsawi, K., Al Ismaily, A., Al-Suwaid, R., Atherton, D.J., Caputo, R., Fine, J.D., Frieden, I.J., Fuchs, E., Haber, R.M., Harada, T., Kitajima, Y., Mallory, S.B., Ogawa, H., Sahin, S., Shimizu, H., Suga, Y., Tadini, G., Tsuchiya, K., Wiebe, C.B., Wojnarowska, F., Zaghloul, A.B., Hamada, T., Mallipeddi, R., Eady, R.A., McLean, W.H., McGrath, J.A., Epstein, E.H., Loss of kindlin-1, a human homolog of the Caenorhabditis elegans actin-extracellular-matrix linker protein UNC-112, causes Kindler syndrome. Am. J. Hum. Genet. 73 (2003), 174–187.
9. [9] Lai-Cheong, J.E., McGrath, J.A., Kindler syndrome. Dermatol. Clin. 28 (2010), 119–124.
10. [10] Has, C., Castiglia, D., del Rio, M., Diez, M.G., Piccinni, E., Kiritsi, D., Kohlhase, J., Itin, P., Martin, L., Fischer, J., Zambruno, G., Bruckner-Tuderman, L., Kindler syndrome: extension of FERMT1 mutational spectrum and natural history. Hum. Mutat. 32 (2011), 1204–1212.
11. [11] Chung, H.J., Uitto, J., Type VII collagen: the anchoring fibril protein at fault in dystrophic epidermolysis bullosa. Dermatol. Clin. 28 (2010), 93–105.
12. [12] Christiano, A.M., Hoffman, G.G., Chung-Honet, L.C., Lee, S., Cheng, W., Uitto, J., Greenspan, D.S., Structural organization of the human type VII collagen gene (COL7A1), composed of more exons than any previously characterized gene. Genomics 21 (1994), 169–179.
13. [13] Varki, R., Sadowski, S., Uitto, J., Pfendner, E., Epidermolysis bullosa. II. Type VII collagen mutations and phenotype/genotype correlations in the dystrophic subtypes. J. Med. Genet. 44 (2007), 181–192.
14. [14] Ryynanen, J., Sollberg, S., Parente, M.G., Chung, L.C., Christiano, A.M., Uitto, J., Type VII collagen gene expression by cultured human cells and in fetal skin. Abundant mRNA and protein levels in epidermal keratinocytes. J. Clin. Invest. 89 (1992), 163–168.
15. [15] Uitto, J., Bruckner-Tuderman, L., Christiano, A.M., McGrath, J.A., Has, C., South, A.P., Kopelan, B., Robinson, E.C., Progress toward treatment and cure of epidermolysis bullosa: summary of the DEBRA International Research Symposium EB2015. J. Invest. Dermatol. 136 (2016), 352–358.
16. [16] Fine, J.D., Johnson, L.B., Weiner, M., Li, K.P., Suchindran, C., Epidermolysis bullosa and the risk of life-threatening cancers: the national EB registry experience, 1986–2006. J. Am. Acad. Dermatol. 60 (2009), 203–211.
17. [17] McGrath, J.A., Schofield, O.M., Mayou, B.J., McKee, P.H., Eady, R.A., Epidermolysis bullosa complicated by squamous cell carcinoma: report of 10 cases. J. Cutan. Pathol. 19 (1992), 116–123.
18. [18] South, A.P., O'Toole, E.A., Understanding the pathogenesis of recessive dystrophic epidermolysis bullosa squamous cell carcinoma. Dermatol. Clin. 28 (2010), 171–178.
19. [19] Martins, V.L., Vyas, J.J., Chen, M., Purdie, K., Mein, C.A., South, A.P., Storey, A., McGrath, J.A., O'Toole, E.A., Increased invasive behaviour in cutaneous squamous cell carcinoma with loss of basement-membrane type VII collagen. J. Cell Sci. 122 (2009), 1788–1799.
20. [20] Ng, Y.Z., Pourreyron, C., Salas-Alanis, J.C., Dayal, J.H., Cepeda-Valdes, R., Yan, W., Wright, S., Chen, M., Fine, J.D., Hogg, F.J., McGrath, J.A., Murrell, D.F., Leigh, I.M., Lane, E.B., South, A.P., Fibroblast-derived dermal matrix drives development of aggressive cutaneous squamous cell carcinoma in patients with recessive dystrophic epidermolysis bullosa. Cancer Res. 72 (2012), 3522–3534.
21. [21] Mittapalli, V.R., Madl, J., Loffek, S., Kiritsi, D., Kern, J.S., Romer, W., Nystrom, A., Bruckner-Tuderman, L., Injury-driven stiffening of the dermis expedites skin carcinoma progression. Cancer Res. 76 (2016), 940–951.
22. [22] Alexeev, V., Donahue, A., Uitto, J., Igoucheva, O., Analysis of chemotactic molecules in bone marrow-derived mesenchymal stem cells and the skin: Ccl27-Ccr10 axis as a basis for targeting to cutaneous tissue. Cytotherapy, 15, 2013 171-184.e171.
23. [23] Takeichi, T., Liu, L., Fong, K., Ozoemena, L., McMillan, J.R., Salam, A., Campbell, P., Akiyama, M., Mellerio, J.E., McLean, W.H., Simpson, M.A., McGrath, J.A., Whole-exome sequencing improves mutation detection in a diagnostic epidermolysis bullosa laboratory. Br. J. Dermatol. 172 (2015), 94–100.
24. [24] Takeichi, T., Nanda, A., Liu, L., Salam, A., Campbell, P., Fong, K., Akiyama, M., Ozoemena, L., Stone, K.L., Al-Ajmi, H., Simpson, M.A., McGrath, J.A., Impact of next generation sequencing on diagnostics in a genetic skin disease clinic. Exp. Dermatol. 22 (2013), 825–831.
25. [25] Christiano, A.M., LaForgia, S., Paller, A.S., McGuire, J., Shimizu, H., Uitto, J., Prenatal diagnosis for recessive dystrophic epidermolysis bullosa in 10 families by mutation and haplotype analysis in the type VII collagen gene (COL7A1). Mol. Med. 2 (1996), 59–76.
26. [26] Uitto, J., Progress in heritable skin diseases: translational implications of mutation analysis and prospects of molecular therapies. Acta Derm. Venereol. 89 (2009), 228–235.
27. [27] Vendrell, X., Bautista-Llacer, R., Alberola, T.M., Garcia-Mengual, E., Pardo, M., Urries, A., Sanchez, J., Pregnancy after PGD for recessive dystrophic epidermolysis bullosa inversa: genetics and preimplantation genetics. J. Assist. Reprod. Genet. 28 (2011), 825–832.
28. [28] Uitto, J., Epidermolysis bullosa: prospects for cell-based therapies. J. Invest. Dermatol. 128 (2008), 2140–2142.
29. [29] Uitto, J., Cell-based therapy for RDEB: how does it work?. J. Invest. Dermatol. 131 (2011), 1597–1599.
30. [30] Nystrom, A., Bruckner-Tuderman, L., Kern, J.S., Cell- and protein-based therapy approaches for epidermolysis bullosa. Methods Mol. Biol. 961 (2013), 425–440.
31. [31] Vanden Oever, M.J., Tolar, J., Advances in understanding and treating dystrophic epidermolysis bullosa. F1000Prime Rep, 6, 2014, 35.
32. [32] Wagner, J.E., Ishida-Yamamoto, A., McGrath, J.A., Hordinsky, M., Keene, D.R., Woodley, D.T., Chen, M., Riddle, M.J., Osborn, M.J., Lund, T., Dolan, M., Blazar, B.R., Tolar, J., Bone marrow transplantation for recessive dystrophic epidermolysis bullosa. N. Engl. J. Med. 363 (2010), 629–639.
33. [33] Tolar, J., Wagner, J.E., Allogeneic blood and bone marrow cells for the treatment of severe epidermolysis bullosa: repair of the extracellular matrix. Lancet 382 (2013), 1214–1223.
34. [34] Perdoni, C., McGrath, J.A., Tolar, J., Preconditioning of mesenchymal stem cells for improved transplantation efficacy in recessive dystrophic epidermolysis bullosa. Stem Cell Res. Ther., 5, 2014, 121.
35. [35] Rashidghamat, E., Mellerio, J.E., Martinez, A.E., McGrath, J.A., Mesenchymal stem cell therapy for recessive dystrophic epidermolysis bullosa: prospects and clinical progress. Expert Opin. Orphan Drugs 4 (2016), 343–345.
36. [36] Turczynski, S., Titeux, M., Pironon, N., Hovnanian, A., Antisense-mediated exon skipping to reframe transcripts. Methods Mol. Biol. 867 (2012), 221–238.
37. [37] Sakuntabhai, A., Hammami-Hauasli, N., Bodemer, C., Rochat, A., Prost, C., Barrandon, Y., de Prost, Y., Lathrop, M., Wojnarowska, F., Bruckner-Tuderman, L., Hovnanian, A., Deletions within COL7A1 exons distant from consensus splice sites alter splicing and produce shortened polypeptides in dominant dystrophic epidermolysis bullosa. Am. J. Hum. Genet. 63 (1998), 737–748.
38. [38] Hovnanian, A., Systemic protein therapy for recessive dystrophic epidermolysis bullosa: how far are we from clinical translation?. J. Invest. Dermatol. 133 (2013), 1719–1721.
39. [39] Bruckner-Tuderman, L., Can type VII collagen injections cure dystrophic epidermolysis bullosa?. Mol. Ther. 17 (2009), 6–7.
40. [40] Kühl, T., Mezger, M., Hausser, I., Guey, L.T., Handgretinger, R., Bruckner-Tuderman, L., Nyström, A., Collagen VII half-life at the dermal-epidermal junction zone: implications for mechanisms and therapy of genodermatoses. J. Invest. Dermatol. 136 (2016), 1116–1123.
41. [41] Fritsch, A., Loeckermann, S., Kern, J.S., Braun, A., Bosl, M.R., Bley, T.A., Schumann, H., von Elverfeldt, D., Paul, D., Erlacher, M., Berens von Rautenfeld, D., Hausser, I., Fassler, R., Bruckner-Tuderman, L., A hypomorphic mouse model of dystrophic epidermolysis bullosa reveals mechanisms of disease and response to fibroblast therapy. J. Clin. Invest. 118 (2008), 1669–1679.
42. [42] Kuhl, T., Mezger, M., Hausser, I., Handgretinger, R., Bruckner-Tuderman, L., Nystrom, A., High local concentrations of intradermal MSCs restore skin integrity and facilitate wound healing in dystrophic epidermolysis bullosa. Mol. Ther. 23 (2015), 1368–1379.
43. [43] Bachinger, H.P., Morris, N.P., Lunstrum, G.P., Keene, D.R., Rosenbaum, L.M., Compton, L.A., Burgeson, R.E., The relationship of the biophysical and biochemical characteristics of type VII collagen to the function of anchoring fibrils. J. Biol. Chem. 265 (1990), 10095–10101.
44. [44] Regauer, S., Seiler, G.R., Barrandon, Y., Easley, K.W., Compton, C.C., Epithelial origin of cutaneous anchoring fibrils. J. Cell Biol. 111 (1990), 2109–2115.
45. [45] Verzijl, N., DeGroot, J., Thorpe, S.R., Bank, R.A., Shaw, J.N., Lyons, T.J., Bijlsma, J.W., Lafeber, F.P., Baynes, J.W., TeKoppele, J.M., Effect of collagen turnover on the accumulation of advanced glycation end products. J. Biol. Chem. 275 (2000), 39027–39031.
46. [46] Urich, D., Eisenberg, J.L., Hamill, K.J., Takawira, D., Chiarella, S.E., Soberanes, S., Gonzalez, A., Koentgen, F., Manghi, T., Hopkinson, S.B., Misharin, A.V., Perlman, H., Mutlu, G.M., Budinger, G.R., Jones, J.C., Lung-specific loss of the laminin alpha3 subunit confers resistance to mechanical injury. J. Cell Sci. 124 (2011), 2927–2937.
47. [47] Kern, J.S., Loeckermann, S., Fritsch, A., Hausser, I., Roth, W., Magin, T.M., Mack, C., Muller, M.L., Paul, O., Ruther, P., Bruckner-Tuderman, L., Mechanisms of fibroblast cell therapy for dystrophic epidermolysis bullosa: high stability of collagen VII favors long-term skin integrity. Mol. Ther. 17 (2009), 1605–1615.
48. [48] Schwieger-Briel, A., Chakkittakandiyil, A., Lara-Corrales, I., Aujla, N., Lane, A.T., Lucky, A.W., Bruckner, A.L., Pope, E., Instrument for scoring clinical outcome of research for epidermolysis bullosa: a consensus-generated clinical research tool. Pediatr. Dermatol. 32 (2015), 41–52.
49. [49] Fine, J.D., Mellerio, J.E., Extracutaneous manifestations and complications of inherited epidermolysis bullosa: part I. Epithelial associated tissues. J. Am. Acad. Dermatol. 61 (2009), 367–384 quiz 385-366.
50. [50] Fine, J.D., Mellerio, J.E., Extracutaneous manifestations and complications of inherited epidermolysis bullosa: part II. Other organs. J. Am. Acad. Dermatol. 61 (2009), 387–402.
51. [51] Küttner, V., Mack, C., Rigbolt, K.T.G., Kern, J.S., Schilling, O., Busch, H., Bruckner-Tuderman, L., Dengjel, J., Global remodeling of cellular microenvironment due to loss of collagen VII. Mol. Syst. Biol., 9, 2013, 657.
52. [52] Nyström, A., Velati, D., Mittapalli, V.R., Fritsch, A., Kern, J.S., Bruckner-Tuderman, L., Collagen VII plays a dual role in wound healing. J. Clin. Invest. 123 (2013), 3498–3509.
53. [53] Nyström, A., Thriene, K., Mittapalli, V., Kern, J.S., Kiritsi, D., Dengjel, J., Bruckner-Tuderman, L., Losartan ameliorates dystrophic epidermolysis bullosa and uncovers new disease mechanisms. EMBO Mol. Med. 7 (2015), 1211–1228.
54. [54] Akhurst, R.J., Hata, A., Targeting the TGFbeta signalling pathway in disease. Nat. Rev. Drug Discov. 11 (2012), 790–811.
55. [55] Albrengues, J., Bourget, I., Pons, C., Butet, V., Hofman, P., Tartare-Deckert, S., Feral, C.C., Meneguzzi, G., Gaggioli, C., LIF mediates proinvasive activation of stromal fibroblasts in cancer. Cell Rep. 7 (2014), 1664–1678.
56. [56] Lacro, R.V., Dietz, H.C., Mahony, L., Atenolol versus losartan in Marfan's syndrome. N. Engl. J. Med. 372 (2015), 980–981.
57. [57] Vahidnezhad, H., Youssefian, L., Saeidian, A.H., Mozafari, N., Barzegar, M.R., Sotoudeh, S., Daneshpazhooh, M., Isaian, A., Zeinali, S., Uitto, J., KRT5 and KRT14 mutations in epidermolysis bullosa simplex with phenotypic heterogeneity, and evidence of semi-dominant inheritance in a multiplex family. J. Invest. Dermatol. 136 (2016), 1897–1901.
58. [58] McGrath, J.A., Bolling, M.C., Jonkman, M.F., Lethal acantholytic epidermolysis bullosa. Dermatol. Clin. 28 (2010), 131–135.
59. [59] McLean, W.H., Irvine, A.D., Hamill, K.J., Whittock, N.V., Coleman-Campbell, C.M., Mellerio, J.E., Ashton, G.S., Dopping-Hepenstal, P.J., Eady, R.A., Jamil, T., Phillips, R., Shabbir, S.G., Haroon, T.S., Khurshid, K., Moore, J.E., Page, B., Darling, J., Atherton, D.J., Van Steensel, M.A., Munro, C.S., Smith, F.J., McGrath, J.A., An unusual N-terminal deletion of the laminin alpha3a isoform leads to the chronic granulation tissue disorder laryngo-onycho-cutaneous syndrome. Hum. Mol. Genet. 12 (2003), 2395–2409.
60. [60] Turcan, I., Pasmooij, A.M.G., van den Akker, P.C., Lemmink, H., Halmos, G.B., Sinke, R.J., Jonkman, M.F., Heterozygosity for a novel missense mutation in the ITGB4 gene associated with autosomal dominant epidermolysis bullosa. JAMA Dermatol. 153 (2016), 558–562.
61. [61] Has, C., Sparta, G., Kiritsi, D., Weibel, L., Moeller, A., Vega-Warner, V., Waters, A., He, Y., Anikster, Y., Esser, P., Straub, B.K., Hausser, I., Bockenhauer, D., Dekel, B., Hildebrandt, F., Bruckner-Tuderman, L., Laube, G.F., Integrin alpha3 mutations with kidney, lung, and skin disease. N. Engl. J. Med. 366 (2012), 1508–1514.
62. [62] Youssefian, L., Vahidnezhad, H., Hossein Saeidian, A., Ahmadizadeh, K., Has, C., Uitto, J., Kindler syndrome, an orphan disease of cell/matrix adhesion in the skin — molecular genetics and therapeutic opportunities. Expert Opin. Orphan Drugs 4 (2016), 845–854.